Dharma Biomedical LLC

Miami, FL, United States

Dharma Biomedical LLC

Miami, FL, United States
SEARCH FILTERS
Time filter
Source Type

Ramachandran C.,Miami Childrens Hospital | Ramachandran C.,Dharma Biomedical LLC | Lollett I.V.,Dharma Biomedical LLC | Escalon E.,Miami Childrens Hospital | And 3 more authors.
Journal of Evidence-Based Complementary and Alternative Medicine | Year: 2015

Mango ginger (Curcuma amada Roxb.) is among the less-investigated species of Curcuma for anticancer properties. We have investigated the anticancer potential and the mechanism of action of a supercritical CO2 extract of mango ginger (CA) in the U-87MG human glioblastoma cell line. CA demonstrated higher cytotoxicity than temozolomide, etoposide, curcumin, and turmeric force with IC50, IC75, and IC90 values of 4.92 μg/mL, 12.87 μg/mL, and 21.30 μg/mL, respectively. Inhibitory concentration values of CA for normal embryonic mouse hypothalamus cell line (mHypoE-N1) is significantly higher than glioblastoma cell line, indicating the specificity of CA against brain tumor cells. CompuSyn analysis indicates that CA acts synergistically with temozolomide and etoposide for the cytotoxicity with combination index values of <1. CA treatment also induces apoptosis in glioblastoma cells in a dose-dependent manner and downregulates genes associated with apoptosis, cell proliferation, telomerase activity, oncogenesis, and drug resistance in glioblastoma cells. © The Author(s) 2014.


Ramachandran C.,Miami Childrens Hospital | Ramachandran C.,Dharma Biomedical LLC | Quirin K.-W.,Flavex Naturextrakte GmbH | Escalon E.A.,Miami Childrens Hospital | And 3 more authors.
Phytotherapy Research | Year: 2015

Synergistic effect of supercritical CO2 extracts of Curcuma species with conventional chemotherapeutic drugs was investigated in human alveolar (SJRH30) and embryonal (RD) rhabdomyosarcoma cell lines. The Curcuma amada (mango ginger) (CA) extract showed the highest levels of cytotoxicity with inhibitory concentration IC50 values of 7.133 μg/ml and 7.501 μg/ml for SJRH30 and RD cell lines, respectively, as compared with Curcuma longa (turmeric) and Curcuma xanthorrhiza (Javanese turmeric) extracts. CA showed synergistic cytotoxic effects with vinblastine (VBL) and cyclophosphamide (CP) as indicated by the combination index values of <1 for VBL + CA, CP + CA, and VBL + CP + CA combinations in both embryonal and alveolar rhabdomyosarcomas. When lower doses of CA (0.1-0.2 μg/ml) were combined with cancer drugs like CP and VBL, caspase-3 activity increased significantly compared with individual agents and correlated with the percentage of apoptotic cells. CA in combination with VBL and CP induced a higher percentage of apoptosis than single agents in both cell lines. CA also modulated the expression of genes associated with intrinsic pathway of apoptosis (Bcl-2, Bax, Bak, and p53) and also inhibited the expression of genes associated with inflammation such as COX-2 and NF-κB. Xenograft studies with SJRH30 tumors in nude mice showed that CA treatment inhibited tumor growth rate with and without VBL and increased the survival rate significantly. These results suggest that CA can be evaluated further as an adjuvant with cancer drugs for the treatment of rhabdomyosarcoma patients. © 2015 John Wiley & Sons, Ltd.


Ramachandran C.,Dharma Biomedical LLC | Ramachandran C.,Miami Childrens Hospital | Quirin K.-W.,Flavex Naturextrakte GmbH | Escalon E.,Miami Childrens Hospital | And 2 more authors.
Journal of Evidence-Based Complementary and Alternative Medicine | Year: 2014

Ethnobotanical evidence suggests that herbs such as brahmi (Bacopa monnieri) and rosemary (Rosmarinus officinalis) may possess antioxidant and neuroprotective properties. We compared the antioxidant and neuroprotective effects of supercritical extract of Bacopa monnieri and rosemary antioxidant extract obtained from Rosmarinus officinalis as well as their combination to examine the effects on human glial (U-87 MG) and embryonic mouse hypothalamus cells. Bacopa monnieri extract, rosemary antioxidant extract, and their combination (1:1) are not cytotoxic in both glial and embryonic mouse hypothalamus cell lines up to 200 μg/mL concentration. The combination of extracts of Bacopa monnieri + rosemary antioxidant has better antioxidant potential and antilipid peroxidation activity than either agent alone. Although the extract of Bacopa monnieri + rosemary antioxidant showed almost similar inhibition of phospho tau expression as Bacopa monnieri or rosemary antioxidant extract alone, the combination has better inhibitory effect on amyloid precursor protein synthesis and higher brain-derived neurotrophic factor production in hypothalamus cells than single agents. These results suggest that the extract of Bacopa monnieri + rosemary antioxidant is more neuroprotective than Bacopa monnieri or rosemary antioxidant extract. © The Author(s) 2014.


Ramachandran C.,Dharma Biomedical LLC | Wilk B.J.,Econugenics Inc. | Hotchkiss A.,U.S. Department of Agriculture | Chau H.,U.S. Department of Agriculture | And 3 more authors.
BMC Complementary and Alternative Medicine | Year: 2011

Background: Modified citrus pectin (MCP) is known for its anti-cancer effects and its ability to be absorbed and circulated in the human body. In this report we tested the ability of MCP to induce the activation of human blood lymphocyte subsets like T, B and NK-cells.Methods: MCP treated human blood samples were incubated with specific antibody combinations and analyzed in a flow cytometer using a 3-color protocol. To test functionality of the activated NK-cells, isolated normal lymphocytes were treated with increasing concentrations of MCP. Log-phase PKH26-labeled K562 leukemic cells were added to the lymphocytes and incubated for 4 h. The mixture was stained with FITC-labeled active form of caspase 3 antibody and analyzed by a 2-color flow cytometry protocol. The percentage of K562 cells positive for PKH26 and FITC were calculated as the dead cells induced by NK-cells. Monosaccharide analysis of the MCP was performed by high-performance anion-exchange chromatography with pulse amperometric detection (HPAEC-PAD).Results: MCP activated T-cytotoxic cells and B-cell in a dose-dependent manner, and induced significant dose-dependent activation of NK-cells. MCP-activated NK-cells demonstrated functionality in inducing cancer cell death. MCP consisted of oligogalacturonic acids with some containing 4,5-unsaturated non-reducing ends.Conclusions: MCP has immunostimulatory properties in human blood samples, including the activation of functional NK cells against K562 leukemic cells in culture. Unsaturated oligogalacturonic acids appear to be the immunostimulatory carbohydrates in MCP. © 2011 Ramachandran et al; licensee BioMed Central Ltd.


Patent
Dharma Biomedical Llc and Flavex Naturextrakte Gmbh | Date: 2016-01-31

The invention concerns carbon dioxide extracts of Curcuma amada (mango ginger), including supercritical carbon dioxide extracts of C. amada; methods for their production; compositions comprising the extracts; methods for treating or delaying the onset of conditions such as cell proliferation disorder (e.g., cancer), inflammation, infection, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, platelet hyper-aggregation, immune disorder such as autoimmune disorder, or neurodegenerative condition; and methods for inhibiting expression of Bcl-2, Bak, and p53 genes; inhibiting expression of the COX-2 and NF-kB genes, inhibiting production of phosphorylated target of rapamycin (TOR), modulating AMP-activated protein kinase (AMPK), inhibiting protein kinase B (AKT) signaling, modulating the Ras/Raf/MEK/ERK signaling pathway, and modulating the Ras/PI3K/PTEN/Akt/mTOR signaling pathway. Another aspect of the invention concerns a method for inhibiting contamination, comprising applying the extract or composition of the invention to a surface. Another aspect of the invention concerns a method for promoting longevity of a cell in vitro or in vivo, comprising contacting a target cell in vitro or in vivo with an effective amount of the extract or composition of the invention. Another aspect of the invention concerns a method for promoting longevity of a subject, comprising administering an effective amount of the extract or composition of the invention. Another aspect of the invention concerns a method for inhibiting the metabolism of a cancer cell, comprising contacting the target cancer cell in vitro or in vivo with an effective amount of the extract or composition of the invention. Another aspect of the invention concerns a kit including the extract or composition; a container containing the extract or composition; and packaging material.


Patent
Dharma Biomedical Llc and Flavex Naturextrakte Gmbh | Date: 2013-01-11

The subject invention pertains to supercritical carbon dioxide extracts of Commiphora mukul resin (guggul), which can be modified or not modified by some ethanol addition; methods for their production; and methods of use, such as inhibiting HMG-CoA reductase, inhibiting transformation of pre-adipocytes to adipocytes, inhibiting triglyceride storage, promoting insulin sensitivity in adipocytes, treatment of disorders (for example, hypercholesterolemia, hyperlipidemia, hyperglycemia, obesity, metabolic syndrome, cardiovascular disease, atherosclerotic heart disease, autoimmune disorder, insulin resistance, leptin resistance, arthritis, cell proliferation disorder, such as cancer and atherosclerosis; damaged skin, sores, cuts, rashes, bruises, dryness, burns, sunburn, radiation burn, and infection), and regulating or suppressing appetite.


Aviram A.,Miami Childrens Hospital | Tsoukias N.M.,Florida International University | Melnick S.J.,Miami Childrens Hospital | Melnick S.J.,Dharma Biomedical LLC | And 3 more authors.
Phytotherapy Research | Year: 2012

Feverfew is the most commonly used medicinal herb against migraine headache. The antimigraine mechanism of feverfew supercritical extract was investigated in vitro using the mouse macrophage cell line (RAW 264.7). Mouse macrophage cells were treated with lipopolysaccharide in the presence and absence of feverfew extracts. Inhibition of lipopolysaccharide-induced nitric oxide and TNF-α synthesis were quantified by ELISA. The mRNA and protein expression of iNOS and eNOS genes were analysed by RT-PCR and western blot analysis, respectively. The feverfew extract inhibited both nitric oxide (NO) and TNF-α production in a dose-dependent manner with complete inhibition of NO occurring at 5 μg/mL of feverfew extract. Both eNOS and iNOS mRNA levels were unchanged with the feverfew treatment. However, eNOS and iNOS proteins were significantly down-regulated by the feverfew extract. Feverfew inhibition of NO is due to the down-regulation of both eNOS and iNOS enzymes at the translational and/or post-translational level. Copyright © 2011 John Wiley & Sons, Ltd.


Ramachandran C.,Miami Childrens Hospital | Ramachandran C.,Dharma Biomedical LLC | Resek A.P.,Miami Childrens Hospital | Resek A.P.,Dharma Biomedical LLC | And 4 more authors.
Oncology Reports | Year: 2010

Gemcitabine is a first line cancer drug widely used for the treatment of pancreatic cancer. However, its therapeutic efficiency is significantly limited by resistance of pancreatic cancer cells to this and other chemotherapeutic drugs. We have investigated the cytotoxic effect of Turmeric Force™ (TF), a supercritical and hydroethanolic extract of turmeric, alone and in combination with gemcitabine in two pancreatic carcinoma cell lines (BxPC3 and Panc-1). TF is highly cytotoxic to BxPC3 and Panc-1 cell lines with IC50 values of 1.0 and 1.22 μg/ml, respectively with superior cytotoxicity than curcumin. Gemcitabine IC50 value for both of these cell line is 0.03 μg/ml; however, 30-48% of the pancreatic cancer cells are resistant to gemcitabine even at concentrations >100 μg/ml. In comparison, TF induced cell death in 96% of the cells at 50 μg/ml. The combination of gemcitabine and TF was synergistic with IC90 levels achieved in both pancreatic cancer cell lines at lower concentrations. CalcuSyn analysis of cytotoxicity data showed that the Gemcitabine + Turmeric Force combination has strong synergism with combination index (CI) values of 0.050 and 0.183 in BxPC3 and Panc-1 lines, respectively at IC50 level. This synergistic effect is due to the increased inhibitory effect of the combination on nuclear factor-κ B activity and signal transducer and activator of transcription factor 3 expression as compared to the single agent.


Trademark
Dharma Biomedical LLC | Date: 2011-02-28

Cosmeceuticals, namely, biologically active plant and herb extracts for use in the manufacture of cosmetics. Dietary supplements and nutraceuticals for use as dietary supplements, all comprising plant, herb and botanical extracts for use as additives to food to promote nutrient absorption, glucose metabolism, blood lipid metabolism, mitochondrial biogenesis, primary energy production, increased catabolism and reduced lipid production, sold in powder, liquid, liposomal, nanoencapsulation, and nanoemulsion forms; cosmeceuticals, namely, medicated skin care preparations; cosmeceuticals, namely, nutritional supplements in lotion form sold as a component of nutritional skin care products.


Trademark
Dharma Biomedical LLC | Date: 2011-02-28

Dietary supplements and nutraceuticals for use as dietary supplements, all comprising plant, herb and botanical extracts for use as additives to food to promote nutrient absorption, immune competence, immune regulation, immune support, immune recognition, immune response signaling, effective immune-mediated inflammatory responsiveness, natural killer cell activation, cell protection, immunemediated healthy cell function and antioxidant protection, sold in powder, liquid, liposomal, nanoencapsulation, and nanoemulsion forms.

Loading Dharma Biomedical LLC collaborators
Loading Dharma Biomedical LLC collaborators